---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: EMBARQ-CSU2"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: EMBARQ-CSU2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 52 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence/embarq-csu2"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: EMBARQ-CSU2

<a id="heading-3.1.2"></a>

## 3.1.2 EMBARQ-CSU2

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.1-2"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.1-3"></a>

#### Aim of the two phase 3 trials stated by the company

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Active, not recruiting”
> “Study Start (Actual) 2024-07-19”
> “Primary Completion (Actual) 2026-08-04”
> “Study Completion (Estimated) 2027-06”
> “First Posted 2024-06-12”
> “Last Update Posted 2026-11-12”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.2-2"></a>

#### Number of locations and EU trial number in the ClinicalTrials.gov record

> “This study has 245 locations”
> “2024-513210-36-00 ( EU Trial (CTIS) Number )”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.2-3"></a>

#### Initiation of the phase 3 trials in July 2024

> “HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.2.2-4"></a>

#### Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2

> “HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2.”
> “The studies included 43 countries and over 500 sites.”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

<a id="topic-3.1.2.2-5"></a>

#### Data cutoff for the topline results

> “Data cutoff: September 9, 2026”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.2-6"></a>

#### Treatment continuing to 52 weeks with 16 weeks of follow-up

> “Patients continue to be treated through 52 weeks, and will be followed for 16 weeks after completion of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”
> “This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.3-2"></a>

#### Study periods in the ClinicalTrials.gov record

> “There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.3-3"></a>

#### Randomization ratio and study periods in the topline presentation

> “Two randomized, double-blind, placebo-controlled, parallel group studies in moderate to severe CSU”
> “1:1:1”
> “24 Week Placebo Controlled Treatment Period”
> “28 Week Active Treatment Period”
> “16 Week Follow Up Period”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.3-4"></a>

#### Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies.”
> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks.”
> “At 24 weeks, patients on placebo were re-randomized to active treatment across both dosing groups.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.3-5"></a>

#### Placebo for 52 weeks and 16-week follow-up in the Form 10-Q

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where patients have been randomized evenly per trial to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”
> “At 24 weeks, patients on placebo are re-randomized to active treatment across both dosing groups.”
> “After completion of the 52 week treatment period, patients on study are followed for 16 weeks.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.2.3-6"></a>

#### Timing of the primary endpoint analysis at 24 weeks

> “The primary endpoint analysis was performed when all patients completed the placebo controlled portion of the study at 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.3-7"></a>

#### Entry into the phase 3b long-term extension after the trial

> “A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Males and females, >/= 18 years of age.”
> “Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).”
> “The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.”
> “UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.”
> “Normal blood counts and liver function tests.”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”
> “Participants with and without prior biologic experience are eligible.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant or nursing.”
> “Chronic urticaria whose predominant manifestation is due to CIndU.”
> “Other diseases associated with urticaria.”
> “Active pruritic skin condition in addition to CSU.”
> “Known HIV, hepatitis B or hepatitis C infection.”
> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study).”
> “History of anaphylaxis”
> “Prior treatment with barzolvolimab”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.4-3"></a>

#### Population summarized in the topline presentation

> “Antihistamine refractory CSU, (1-4x approved dose) including patients with advanced therapy experienced/refractory CSU”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.5-2"></a>

#### Arms with loading doses in the topline presentation

> “Arm 1 Barzolvolimab 300 mg LD + 150 mg Q4 WK”
> “Arm 2 Barzolvolimab 450 mg LD + 300 mg Q8 WK”
> “Arm 3 Placebo Q4 WK”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Weekly Urticaria Activity Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)”
> “The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.”
> “From Day 1 (first dose) to Day 85 (Week 12)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.6.1-2"></a>

##### Secondary outcome measures in the current ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)”
> “The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.”
> “Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)”
> “The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.”
> “Percentage of patients with UAS7=0 at Week 12”
> “Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.”
> “Percentage of participants with UAS7 ≤ 6 at Week 12”
> “Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12”
> “Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12”
> “Incidence of Treatment-Emergent Adverse Events”
> “From Day 1 (first dose) to Day 477 (Week 68)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.6.1-3"></a>

##### Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history

> “Comparing V1 (2024-06-07) to V18 (2026-02-03)”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Mean change from baseline in UAS7 at Week 4”
> “[Time Frame: From Day 1 (first dose) to Day 29 (Week 4)]”
> “Mean change from baseline in UAS7 at Week 24”
> “Percentage of participants with UAS7 = 0 at Week 24”
> “[Time Frame: From Day 1 (first dose) to Day 169 (Week 24)]”

Source: [ClinicalTrials.gov NCT06455202 record history](https://clinicaltrials.gov/study/NCT06455202?tab=history&a=1&b=18)

<a id="topic-3.1.2.6.1-4"></a>

##### Key secondary endpoints at Week 12 in the topline presentation

> “Primary Endpoint: mean change from baseline in UAS7 at Week 12”
> “Mean change from baseline in ISS7 and HSS7”
> “Proportion of participants with UAS7=0”
> “Proportion of participants with UAS7≤6”
> “Proportion of participants with AAS7=0 who have AAS7> 0 at baseline”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab”
> “Proportion of participants with UAS7=0 in participants refractory to omalizumab”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.6.1-5"></a>

##### Complete response (UAS7=0) as the treatment goal stated by the company

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.2.6.1-6"></a>

##### Reason given by the company for presenting complete response at Week 24

> “Given the importance of Complete Response (complete absence of itch and hives) to patients and physicians”
> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.7.1-2"></a>

##### Planned enrollment per trial at initiation

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where approximately 915 patients will be randomized evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.2.7.1-3"></a>

##### Statistical power for the primary endpoint

> “90% powered to detect at least a 10-point difference between each of active arm vs placebo in overall population as well as in the subpopulation of omalizumab refractory participants”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.1-4"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 976”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.7.1-5"></a>

##### Participants randomized in the topline release

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.7.1-6"></a>

##### Participants analyzed per arm in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”
> “Placebo Q4W (N=321)”
> “Barzolvolimab 150 mg Q4W (N=324)”
> “Barzolvolimab 300 mg Q8W (N=321)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Full analysis set and primary endpoint model

> “Full analysis set; imputed data and MMRM model”
> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.2-2"></a>

##### Adjusted proportions from logistic regression with multiple imputation

> “Adjusted proportions are based on logistic regression model with multiple imputation method.”
> “The adjusted odds ratios and the proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.2-3"></a>

##### Basis of the p-values in the topline release

> “P-values are for LS Mean treatment difference versus placebo.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.7.2-4"></a>

##### Definition of the omalizumab-refractory subpopulation

> “Patients treated with omalizumab at approved doses for at least 3 months and whose symptoms never responded or who responded initially but symptoms subsequently returned, or who discontinued omalizumab due to intolerance”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participants randomized and enrollment status

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”
> “The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline characteristics in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Characteristic | Placebo every 4 weeks (N=321) | Barzolvolimab 150 mg every 4 weeks (N=324) | Barzolvolimab 300 mg every 8 weeks (N=321) |
| --- | --- | --- | --- |
| Age (years), mean (SD) | “45.7 (14.59)” | “46.2 (14.53)” | “46.2 (14.01)” |
| Female, n (%) | “215 (67.0)” | “229 (70.7)” | “208 (64.8)” |
| Race, White, n (%) | “229 (71.3)” | “225 (69.4)” | “242 (75.4)” |
| Race, Black, n (%) | “6 (1.9)” | “11 (3.4)” | “8 (2.5)” |
| Race, Asian, n (%) | “49 (15.3)” | “54 (16.7)” | “50 (15.6)” |
| Weight (kg), mean (SD) | “80.70 (18.96)” | “78.72 (19.10)” | “79.94 (19.15)” |
| UAS7 score, mean (SD) | “29.3 (7.19)” | “29.7 (6.87)” | “29.6 (7.28)” |
| Severe disease (UAS7 of 28 or more), n (%) | “199 (62.0)” | “203 (62.7)” | “198 (61.7)” |
| Omalizumab refractory, n (%) | “43 (13.4)” | “44 (13.6)” | “42 (13.1)” |
| AAS7 greater than 0, n (%) | “206 (64.2)” | “213 (65.7)” | “217 (67.6)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “50.2 (28.63)” | “51.5 (28.67)” | “51.7 (27.81)” |
| DLQI score, mean (SD) | “14.2 (7.11)” | “14.4 (7.02)” | “14.3 (7.11)” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error

> “Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12:”
> “LS Mean Change (SE) at Week 12”
> “P-values are for LS Mean treatment difference versus placebo.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
| --- | --- | --- |
| Placebo every 4 weeks | “29.3” | “-11.4 (0.64)” |
| Barzolvolimab 150 mg every 4 weeks | “29.7” | “-20.2 (0.63) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “29.6” | “-19.7 (0.64) (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set

> “Treatment Difference LS Mean (97.5% CI):”
> “Full analysis set; imputed data and MMRM model”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
| --- | --- | --- |
| Barzolvolimab 150 mg every 4 weeks | “-8.9 ( -10.9, -6.9)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-8.3 ( -10.4, -6.3)” | “p < .00001” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-3"></a>

##### Complete response (UAS7=0) at Week 12, adjusted proportions

> “Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12 |
| --- | --- |
| Placebo every 4 weeks | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “45.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.0% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (%) (95% CI) of Participants Achieving UAS7=0 at Week 12”
> “Adjusted proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-4"></a>

##### Complete response (UAS7=0) at Week 24 presented by the company

> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 24 |
| --- | --- |
| Placebo every 4 weeks | “17.6%” |
| Barzolvolimab 150 mg every 4 weeks | “54.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “48.4% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.3-5"></a>

##### Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants

> “Proportion of Patients with Complete Response (UAS7=0) at Week 12 in Omalizumab-Refractory CSU”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
| --- | --- |
| Placebo every 4 weeks | “15.1%” |
| Barzolvolimab 150 mg every 4 weeks | “41.7% (p=.0089)” |
| Barzolvolimab 300 mg every 8 weeks | “46.4% (p=.0036)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving UAS7=0 at Week 12 (Omalizumab Refractory)”
> “Placebo (N=43)”
> “Barzovolimab 150 mg Q4W (N=44)”
> “Barzovolimab 300 mg Q8W (N=42)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-6"></a>

##### AAS7=0 at Week 12 in participants with baseline AAS7>0

> “Proportion of Patients with AAS7=0 at Week 12 in Patients with Baseline AAS7>0”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
| --- | --- |
| Placebo every 4 weeks | “33.7%” |
| Barzolvolimab 150 mg every 4 weeks | “74.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.2% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving AAS7=0 at Week 12”
> “Placebo (N=206)”
> “Barzovolimab 150 mg Q4W (N=213)”
> “Barzovolimab 300 mg Q8W (N=217)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-7"></a>

##### Other key secondary endpoints at Week 12 reported as met without values

> “All key secondary endpoints in both EMBARQ-CSU trials were met at Week 12 with high statistical significance and were clinically meaningful.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Trials met key additional secondary endpoints demonstrating consistent and deep responses to barzolvolimab”
> “Mean change from baseline in ISS7 and HSS7”
> “Mean change from baseline in UAS7 in patients refractory to omalizumab”
> “Proportion of patients with UAS7≤6”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Safety statement through the 24-week placebo-controlled period

> “Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
| --- | --- | --- | --- |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-3"></a>

##### Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “AG3 anaphylaxis adjudicated as unlikely”
> “BG2 angioedema/throat tightness/urticaria”
> “CG3 anemia/neutropenia;”
> “G2 malaise/dyspnea/chest pain;”
> “G3 anaphylaxis after placebo administration adjudicated as unlikely”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-4"></a>

##### Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “On barzolvolimab, the vast majority of AEs are mild to moderate”
> “Rate of SAEs similar across treatment groups”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-5"></a>

##### Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “No increased rates of infection in barzolvolimab vs placebo treatment groups”
> “Placebo: 23.9%”
> “150 mg Q4W: 24.4%”
> “300 mg Q8W: 23.6%”
> “Rates of neutropenia in Phase 3 were consistent with Phase 2”
> “Neutropenia Not Associated with Increased Incidence of Infections”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: limitations of the available EMBARQ-CSU2 evidence

- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-06-07) with version 18 (2026-02-03) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (17.6%, 54.0%, and 48.4%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Participant counts are reported from different sources without reconciliation: 976 participants randomized (release) and enrolled (ClinicalTrials.gov), and a full analysis set of N=321, N=324, and N=321 by arm (presentation). The placebo duration also differs: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”. Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 14.2, 14.4, and 14.3), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 43, 44, and 42 participants (13.4%, 13.6%, and 13.1% of each arm), with p-values of .0089 and .0036 for UAS7=0 at Week 12 in this subgroup. The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2); [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202); [ClinicalTrials.gov NCT06455202 record history](https://clinicaltrials.gov/study/NCT06455202?tab=history&a=1&b=18); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
